Date:5/6/2008

e of AtriCure's products, AtriCure's ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure's products, competition from existing and new products and procedures or AtriCure's ability to effectively react to other risks and uncertainties described from time to time in AtriCure's SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation (including the purported class action lawsuit) or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com

ATRICURE, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

Three Months Ended March 31,

2008 2007

Revenues $13,530,145 $10,750,770

Cost of revenues 3,230,880 2,210,495

Gross profit 10,299,265 8,540,275

Operating expenses:

Research and development expenses 2,433,154 3,129,278

Selling, general and

administrative expenses 11,762,426 10,283,187

Total operating
'/>"/>

SOURCE AtriCure, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
2. Genetic Engineering and Biotechnology News (GEN) Reports on Early ADMET Use
3. Vion Reports 2008 First Quarter Results
4. eResearchTechnology Reports First Quarter 2008 Results
5. MannKind Corporation Reports First Quarter Financial Results
6. Verenium Reports Financial Results for the First Quarter 2008
7. ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
8. United Therapeutics Reports First Quarter 2008 Financial Results
9. Endocare Reports 2008 First Quarter Financial Results
10. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
11. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase